

Introducing VisualPap....

VisualPap is an AI-powered, cervical cancer adjunctive screening tool that evaluates the risk of cervical dysplasia, giving an immediate result at the point-of-care.

Integrated into the EVA System colposcope, VisualPap is an adjunctive test performed together with existing screening methods (Pap/ HPV /VIA) in the same patient visit. VisualPap is immediate, accurate and easily implemented.


VisualPap + = the presence of CIN2 or higher lesions is likely.

VisualPap - = no high-risk lesions have been detected by the system

VisualPap offers clinicians an extraordinary new tool to add to their women’s health practice. Immediate results indicating likely precancerous lesions enable clinicians to streamline their cervical cancer screening services, by moving directly to the next appropriate step in the same patient visit. This reassures patients, can help reduce loss to follow up, and reduce administration costs.

How does it fit into the clinical workflow?

Once the speculum has been inserted and the EVA System positioned for visualization, the clinician performs the existing screening test, then proceeds to the VisualPap test at the click of a button for an instant indication of whether pre-cancerous lesions are detected. As soon as the VisualPap process is complete, an immediate assessment is displayed on the EVA System screen. The most appropriate next steps in screening or treatment can then be scheduled.



How was VisualPap developed?

VisualPap is the first commercial product to leverage the power of machine learning for cervical cancer screening using visualization of the cervix. MobileODT data scientists developed the algorithm using cervical images shared with us by research partners around the world, that were exclusively captured with the EVA System and confirmed by biopsy.

Using the most rigorous verification standards, VisualPap was tested with unique datasets ensuring the highest in AI quality control methods.

VisualPap is MobileODT's version of Automated Visual Evaluation (AVE), the approach to visual cervical cancer screening first publicly identified by the National Cancer Institute of the US and the National Library of Medicine. MobileODT participated in that original research, and MobileODT's data scientists applied AVE to MobileODT's unique dataset to create a clinically useful product.

"We demonstrated that the digital images taken with this device [the EVA System] work for such an algorithm [AVE]..."

I think the technology is powerful and has the potential to be a gamechanger for point of care decisions about treatment."

- *Dr. Nicholas Wentzensen, M.D., Ph.D., M.S.*
Deputy Branch Chief at the Division of Cancer Epidemiology and Genetics, National Cancer Institute, IPVC 2018

When will VisualPap be available?

Commercial pilots of VisualPap are currently taking place around the world. If you would like to take part or for more information about VisualPap commercial launch in your region, please contact

Mario Labella - CEO Strena Medical
mlabella@strenamedical.com

About the EVA System



The EVA System is an FDA-cleared, CE-marked smart mobile colposcope and enhanced women's health visual assessment solution. It combines high-quality optics, image and video capture with secure, HIPAA-compliant online data management. Both wireless and lightweight, weighing just 606 grams (1.3 lbs), the EVA System is easily portable between exam rooms or clinic locations. Currently used in 42 countries worldwide, the EVA System is leading the way in women's health innovation.